智飛生物(300122.SZ):GSK將向智飛生物獨家供應重組帶狀皰疹疫苗
格隆匯10月9日丨智飛生物(300122.SZ)公佈,2023年10月8日,公司與葛蘭素史克生物、葛蘭素史克香港(以下合稱:"GSK")簽署了《獨家經銷和聯合推廣協議》,GSK將向智飛生物獨家供應重組帶狀皰疹疫苗,並許可智飛生物根據約定在合作區域內(係指中國大陸)營銷、推廣、進口並經銷有關產品。此外,協議還約定GSK將優先在合作區域內任何RSV老年人疫苗的聯合開發和商業化方面成為智飛生物的獨家合作伙伴。
公吿顯示,本協議確定了重組帶狀皰疹疫苗未來三年的最低年度採購金額,保障了協議產品的基礎供應,若履約正常預計將對公司代理業務的經營收入與營業利潤產生積極影響;本次合作的達成是公司市場推廣實力的體現,顯示出公司專業高效的市場能力和垂直深入的營銷網絡得到了更多商業夥伴的認可。公司將充分利用市場營銷網絡推動協議的正常履行,以進一步鞏固公司發展的核心競爭力,強化公司在市場競爭中的優勢地位;公司將貫徹"技術&市場"雙輪驅動的發展策略,讓市場推廣與技術創新相互促進、雙向賦能。公司代理業務取得的成果為持續加大自主研發投入奠定了堅實的基礎,促進了公司研發創新能力的不斷提升,有利於公司主營業務的全面、健康、可持續發展;公司與GSK不存在關聯關係,本次協議的簽署及履行不會對公司業務獨立性產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.